Immune cell infiltration in colonic cancer: correlation between biopsy and surgical specimens.
暂无分享,去创建一个
N. Demartines | C. Sempoux | P. Yan | D. Speiser | O. Dormond | P. Foukas | N. Bordry | M. Germann | M. Sauvain
[1] R. Labianca,et al. Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] P. Laurent-Puig,et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] A. Broeks,et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.
[4] D. McMillan,et al. Preoperative, biopsy‐based assessment of the tumour microenvironment in patients with primary operable colorectal cancer , 2019, The journal of pathology. Clinical research.
[5] L. Sevenich. Turning “Cold” Into “Hot” Tumors—Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers , 2019, Front. Oncol..
[6] A. Broeks,et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma , 2018, Nature Medicine.
[7] F. Marincola,et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.
[8] F. Mami-Chouaib,et al. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy , 2018, Front. Immunol..
[9] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Z. Trajanoski,et al. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.
[11] S. Tejpar,et al. KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation? , 2015, British Journal of Cancer.
[12] M. Borner,et al. CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival , 2014, Journal of Translational Medicine.
[13] Jérôme Galon,et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.
[14] T. Wiegel,et al. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer. , 2013, Clinical colorectal cancer.
[15] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[16] M. Lai,et al. Colorectal cancer, one entity or three , 2009, Journal of Zhejiang University SCIENCE B.
[17] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[18] C. Ko,et al. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.
[19] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[20] J. Hermans,et al. Mechanisms of oncogenesis in colon versus rectal cancer , 2001, The Journal of pathology.